AN2 THERAPEUTICS INC (ANTX) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ANTX • US0373261058

1.1 USD
+0.02 (+1.85%)
Last: Feb 4, 2026, 10:02 AM
Fundamental Rating

2

Taking everything into account, ANTX scores 2 out of 10 in our fundamental rating. ANTX was compared to 191 industry peers in the Pharmaceuticals industry. While ANTX has a great health rating, there are worries on its profitability. ANTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • ANTX had negative earnings in the past year.
  • ANTX had a negative operating cash flow in the past year.
  • In the past 5 years ANTX always reported negative net income.
  • ANTX had a negative operating cash flow in each of the past 5 years.
ANTX Yearly Net Income VS EBIT VS OCF VS FCFANTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • With a Return On Assets value of -50.55%, ANTX is not doing good in the industry: 62.30% of the companies in the same industry are doing better.
  • ANTX has a Return On Equity (-56.29%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -50.55%
ROE -56.29%
ROIC N/A
ROA(3y)-48.03%
ROA(5y)-106.84%
ROE(3y)-53.15%
ROE(5y)-145.1%
ROIC(3y)N/A
ROIC(5y)N/A
ANTX Yearly ROA, ROE, ROICANTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

  • ANTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANTX Yearly Profit, Operating, Gross MarginsANTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, ANTX has more shares outstanding
  • The number of shares outstanding for ANTX has been increased compared to 5 years ago.
  • There is no outstanding debt for ANTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ANTX Yearly Shares OutstandingANTX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
ANTX Yearly Total Debt VS Total AssetsANTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -3.06, we must say that ANTX is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -3.06, ANTX perfoms like the industry average, outperforming 41.88% of the companies in the same industry.
  • ANTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.06
ROIC/WACCN/A
WACCN/A
ANTX Yearly LT Debt VS Equity VS FCFANTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • ANTX has a Current Ratio of 9.33. This indicates that ANTX is financially healthy and has no problem in meeting its short term obligations.
  • ANTX has a Current ratio of 9.33. This is in the better half of the industry: ANTX outperforms 78.01% of its industry peers.
  • A Quick Ratio of 9.33 indicates that ANTX has no problem at all paying its short term obligations.
  • ANTX has a Quick ratio of 9.33. This is in the better half of the industry: ANTX outperforms 78.01% of its industry peers.
Industry RankSector Rank
Current Ratio 9.33
Quick Ratio 9.33
ANTX Yearly Current Assets VS Current LiabilitesANTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 42.86% over the past year.
EPS 1Y (TTM)42.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ANTX will show a small growth in Earnings Per Share. The EPS will grow by 2.91% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y30.34%
EPS Next 2Y19.75%
EPS Next 3Y14.53%
EPS Next 5Y2.91%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANTX Yearly EPS VS EstimatesANTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ANTX. In the last year negative earnings were reported.
  • Also next year ANTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANTX Price Earnings VS Forward Price EarningsANTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANTX Per share dataANTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

  • ANTX's earnings are expected to grow with 14.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.75%
EPS Next 3Y14.53%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for ANTX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

AN2 THERAPEUTICS INC

NASDAQ:ANTX (2/4/2026, 10:02:49 AM)

1.1

+0.02 (+1.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12
Earnings (Next)03-16
Inst Owners39.36%
Inst Owner Change-0.17%
Ins Owners10.48%
Ins Owner Change-0.97%
Market Cap30.14M
Revenue(TTM)N/A
Net Income(TTM)-33.98M
Analysts43.33
Price Target1.02 (-7.27%)
Short Float %0.25%
Short Ratio0.57
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.01%
Min EPS beat(2)-38.15%
Max EPS beat(2)38.17%
EPS beat(4)2
Avg EPS beat(4)-7.05%
Min EPS beat(4)-38.15%
Max EPS beat(4)38.17%
EPS beat(8)6
Avg EPS beat(8)5%
EPS beat(12)8
Avg EPS beat(12)3.24%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-33.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.09%
EPS NY rev (1m)0%
EPS NY rev (3m)-10.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.5
P/tB 0.5
EV/EBITDA N/A
EPS(TTM)-1.12
EYN/A
EPS(NY)-0.93
Fwd EYN/A
FCF(TTM)-1.08
FCFYN/A
OCF(TTM)-1.08
OCFYN/A
SpS0
BVpS2.2
TBVpS2.2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -50.55%
ROE -56.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.03%
ROA(5y)-106.84%
ROE(3y)-53.15%
ROE(5y)-145.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.33
Quick Ratio 9.33
Altman-Z -3.06
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.43%
EPS Next Y30.34%
EPS Next 2Y19.75%
EPS Next 3Y14.53%
EPS Next 5Y2.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y42.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y32.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.52%
OCF growth 3YN/A
OCF growth 5YN/A

AN2 THERAPEUTICS INC / ANTX FAQ

What is the fundamental rating for ANTX stock?

ChartMill assigns a fundamental rating of 2 / 10 to ANTX.


What is the valuation status for ANTX stock?

ChartMill assigns a valuation rating of 0 / 10 to AN2 THERAPEUTICS INC (ANTX). This can be considered as Overvalued.


How profitable is AN2 THERAPEUTICS INC (ANTX) stock?

AN2 THERAPEUTICS INC (ANTX) has a profitability rating of 0 / 10.


Can you provide the financial health for ANTX stock?

The financial health rating of AN2 THERAPEUTICS INC (ANTX) is 7 / 10.